Literature DB >> 31897534

Differences in medical treatment and clinical characteristics between men and women with heart failure - a single-centre multivariable analysis.

Helena Norberg1,2, Veronica Pranic1, Ellinor Bergdahl1, Krister Lindmark3.   

Abstract

PURPOSE: The aims of this study were to examine sex differences in a heart failure population with regards to treatment and patient characteristics and to investigate the impact of sex on achieved doses of heart failure medications. METHODS AND
RESULTS: A total of 1924 patients with heart failure in a regional hospital were analysed, 622 patients had ejection fraction ≤ 40% of which 30% were women. In patients with reduced ejection fraction, women were older (79 ± 11 vs. 74 ± 12 years, P < 0.001), had lower body weight (70 ± 17 vs. 86 ± 18 kg, P < 0.001), lower estimated glomerular filtration rate (eGFR) (49 ± 24 vs. 71 ± 30 ml/min, P < 0.001) and received lower doses of heart failure medications than men. Multivariable linear regression on patients with reduced ejection fraction showed that sex was not associated with achieved dose of any heart failure medication. For angiotensin-converting enzyme inhibitors and angiotensin receptor blockers associated factors were eGFR, systolic blood pressure, age, ejection fraction, and heart rate. For beta-blockers associated factors were body weight, atrial fibrillation and age. For mineralocorticoid receptor antagonists associated factors were eGFR, serum potassium, age, systolic blood pressure, ejection fraction and heart rate.
CONCLUSION: Women with heart failure and reduced ejection fraction were prescribed lower doses of heart failure medications, were older, had worse renal function, and lower body weight than men. Sex was not independently associated with achieved doses of heart failure medications, instead age, renal function and body weight explained the differences in treatment.

Entities:  

Keywords:  HFrEF; Heart failure; Sex differences; Target dose

Mesh:

Substances:

Year:  2020        PMID: 31897534     DOI: 10.1007/s00228-019-02782-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  35 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012.

Authors:  Tonje Thorvaldsen; Lina Benson; Ulf Dahlström; Magnus Edner; Lars H Lund
Journal:  Eur J Heart Fail       Date:  2016-02-11       Impact factor: 15.534

3.  Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women.

Authors:  Pooja Dewan; Rasmus Rørth; Pardeep S Jhund; Li Shen; Valeria Raparelli; Mark C Petrie; William T Abraham; Akshay S Desai; Kenneth Dickstein; Lars Køber; Ulrik M Mogensen; Milton Packer; Jean L Rouleau; Scott D Solomon; Karl Swedberg; Michael R Zile; John J V McMurray
Journal:  J Am Coll Cardiol       Date:  2019-01-08       Impact factor: 24.094

4.  Sex-related differences in chronic heart failure.

Authors:  Alberto Aimo; Giuseppe Vergaro; Andrea Barison; Silvia Maffei; Chiara Borrelli; Doralisa Morrone; Matteo Cameli; Alberto Palazzuoli; Giuseppe Ambrosio; Stefano Coiro; Ketty Savino; Elisabetta Cerbai; Rossella Marcucci; Roberto Pedrinelli; Luigi Padeletti; Claudio Passino; Michele Emdin
Journal:  Int J Cardiol       Date:  2018-03-15       Impact factor: 4.164

5.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

6.  What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?

Authors:  Pierpaolo Pellicori; Alessia Urbinati; Parin Shah; Alexandra MacNamara; Syed Kazmi; Riet Dierckx; Jufen Zhang; John G F Cleland; Andrew L Clark
Journal:  Eur J Heart Fail       Date:  2017-02-27       Impact factor: 15.534

7.  Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey.

Authors:  P de Groote; R Isnard; P Assyag; P Clerson; A Ducardonnet; M Galinier; G Jondeau; I Leurs; J-F Thébaut; M Komajda
Journal:  Eur J Heart Fail       Date:  2007-12       Impact factor: 15.534

8.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Authors:  Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Salim Yusuf; Stuart Pocock
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

9.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

Review 10.  Sex differences in pharmacokinetics and pharmacodynamics.

Authors:  Offie P Soldin; Donald R Mattison
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more
  2 in total

1.  Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants.

Authors:  Michael Fu; Ola Vedin; Bodil Svennblad; Erik Lampa; Daniel Johansson; Ulf Dahlström; Krister Lindmark; Peter Vasko; Anna Lundberg; Madlaina Costa-Scharplatz; Lars H Lund
Journal:  ESC Heart Fail       Date:  2020-09-03

2.  Sex Differences in Comorbidity, Therapy, and Health Services' Use of Heart Failure in Spain: Evidence from Real-World Data.

Authors:  Anyuli Gracia Gutiérrez; Beatriz Poblador-Plou; Alexandra Prados-Torres; Fernando J Ruiz Laiglesia; Antonio Gimeno-Miguel
Journal:  Int J Environ Res Public Health       Date:  2020-03-23       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.